{"brief_title": "Effects of Arzoxifene on Bone Mass and the Uterus", "brief_summary": "The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects of arzoxifene on the uterus (womb) in postmenopausal women. - The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. - The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. - The safety of arzoxifene and any side effects that might be associated with its use.", "condition": "Postmenopausal Bone Loss", "intervention_type": "Drug", "intervention_name": "Placebo", "criteria": "Inclusion Criteria: - Female - 45 to 60 years of age, inclusive - At least 2 years since last menstrual cycle - Intact uterus (womb). Exclusion Criteria: - Existing fracture of the spine. - Bone disorders, other than low bone mass - History of cancer in the last 5 years. Also, any history, at any time, of breast cancer or cancer of the lining of the uterus. - Abnormal or unexplained vaginal bleeding.", "gender": "Female", "minimum_age": "45 Years", "maximum_age": "60 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00085956.xml"}